ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

RLYB vs INO // FREE CASH FLOW YIELD

Rallybio Corporation (NASDAQ) VS. Inovio Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: RLYB 4 — INO 0
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RLYB VS. INO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC RLYB INO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield ACTIVE — — — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) 34.90% -65.00% +99.90 RLYB /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 4.13 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 RLYB /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 40.4 27.1 +13.39 RLYB /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $83.0M $79.8M $3.2M RLYB /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR RLYB REV INO REV RLYB GROSS % INO GROSS % RLYB FCF INO FCF
FY 2025 $858.0K $65.3K — — -$29.8M -$88.9M
FY 2024 $636.0K $217.8K — — -$49.3M -$104.6M
FY 2023 $0 $832.0K — — -$60.3M -$124.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RLYB // BETA —
INO // BETA —